Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,140
Change Today +15.00 / 1.33%
Volume 1.4M
KAEF On Other Exchanges
Symbol
Exchange
Indonesia
Stuttgart
As of 12:32 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

kimia farma persero tbk pt (KAEF) Snapshot

Open
$1,125
Previous Close
$1,125
Day High
$1,155
Day Low
$1,105
52 Week High
12/9/14 - $1,640
52 Week Low
06/23/14 - $940.00
Market Cap
6.3T
Average Volume 10 Days
2.6M
EPS TTM
$45.95
Shares Outstanding
5.6B
EX-Date
04/16/15
P/E TM
24.8x
Dividend
$8.45
Dividend Yield
0.74%
Current Stock Chart for KIMIA FARMA PERSERO TBK PT (KAEF)

Related News

No related news articles were found.

kimia farma persero tbk pt (KAEF) Related Businessweek News

No Related Businessweek News Found

kimia farma persero tbk pt (KAEF) Details

PT Kimia Farma (Persero) Tbk engages in producing, processing, marketing, and distributing chemical, pharmaceutical, biologic, and other materials required for the production of pharmaceutical, inventories, contraceptives, cosmetics, traditional medicines, medical equipment, food and beverages, and other products in Indonesia. The company operates through Manufacture, Distribution, Retail, and Others segments. It offers pharmaceutical finished products that include non betalactam, betalactam, antiretroviral, narcotic, herbal, hormone contraceptive, generic, oncology, ethical, and over the counter products, as well as intra uterine devices; and eye ointments, skin ointments/creams, quinine and quinine salts, castor oil and edible oils, cosmetics, iodine and iodine salts, and ferrous sulfate raw materials. The company offers its products in various dosage forms, such as tablets, coated tablets, capsules, oral powders, dry syrups, suspensions/syrups, creams, injections, soft capsules, suppository, granules, and phytopharmaca. In addition, it produces packing and indirect materials, machinery and equipment, and other supporting facilities related to pharmaceutical and other industries. The company operates approximately 617 drugstores; and sells its products to pharmacies, hospitals, drugstores, and supermarkets. It exports its products to Asia, Europe, Africa, Australia, and New Zealand. PT Kimia Farma (Persero) Tbk was founded in 1817 and is headquartered in Jakarta, Indonesia.

4,283 Employees
Last Reported Date: 03/5/15
Founded in 1817

kimia farma persero tbk pt (KAEF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kimia farma persero tbk pt (KAEF) Key Developments

Indofarma and Kimia Farma To Merge

The Indonesian government will decide on a planned merger between PT Kimia Farma (Persero) Tbk (JKSE:KAEF) and Pt Indofarma Persero Tbk (JKSE:INAF) in the week ending December 12, 2014. Indonesian state enterprises minister Rini Soemarno said the planned merger between Indofarma and Kimia Farma into a holding company will be a government priority, Bisnis Indonesia quoted her as saying.

PT Kimia Farma Reports Earnings Results for the Nine Months Ended September 2014

PT Kimia Farma reported earnings results for the nine months ended September 2014. The company posted net profit of IDR 143.83 billion (USD 11.82 million) for the first nine months of 2014, up 18.43% from IDR 121.45 billion in the same period a year earlier. The higher net profit came on the back of a 9.22% rise in net sales to IDR 3.08 trillion for the January to September period. The company's operating profit jumped 25.9% to IDR 214 billion for the nine-month period.

PT Kimia Farma Plans to Spend USD 49.5 Million on Business Expansion in 2015

PT Kimia Farma plans to spend IDR 600 billion (USD 49.5 million) on business expansion in 2015. The majority of the funds will be spent on a new plant in Banjaran, West Java, which will have production capacity three to four times that of the factory it is replacing, which currently manufactures quinine and its derivatives, contraceptive products, and other pharmaceutical products. The new plant is expected to be completed in two years. The company also plans to open new pharmacies and clinics, as well as construct a raw materials factory in Watudakon. The company is aiming to open 100 new pharmacies and 50 new clinics in Indonesia in 2015, bringing the total to 612 pharmacies and 250 clinics under operation. To fuel the expansion, the company plans to raise approximately one-third of the capital from internal cash and the remainder from external sources, including bank loans.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KAEF:IJ 1,140.00 +15.00

KAEF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KAEF.
View Industry Companies
 

Industry Analysis

KAEF

Industry Average

Valuation KAEF Industry Range
Price/Earnings 24.3x
Price/Sales 1.3x
Price/Book 3.4x
Price/Cash Flow 22.4x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KIMIA FARMA PERSERO TBK PT, please visit www.kimiafarma.co.id. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.